Cartesian Therapeutics (RNAC) analyst forecast and price target
Analyst forecast
Consensus of 8 analyst ratings
Based on 3 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Wedbush | Maintained | Outperform | $38.00 | Aug 18, 2026 |
| Wedbush | Maintained | Outperform | $38.00 | Jun 10, 2026 |
| BTIG | Maintained | Buy | $44.00 | Jun 9, 2026 |
| Needham | Maintained | Buy | $40.00 | Jun 9, 2026 |
| Wedbush | Maintained | Outperform | $38.00 | May 27, 2026 |
| Needham | Maintained | Buy | $40.00 from $42.00 | May 26, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $25.00 from $30.00 | May 12, 2026 |
| Wedbush | Maintained | Outperform | $38.00 | May 1, 2026 |
| Wedbush | Maintained | Outperform | $38.00 | Mar 10, 2026 |
| Needham | Maintained | Buy | $42.00 | Mar 9, 2026 |
| Cantor Fitzgerald | Upgraded | Neutral → Overweight | $16.00 | Mar 9, 2026 |
| Needham | Maintained | Buy | $42.00 from $40.00 | Jan 9, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $30.00 from $40.00 | Nov 19, 2025 |
| BTIG | Maintained | Buy | $44.00 from $42.00 | Nov 14, 2025 |
| Wedbush | Initiated Coverage | Outperform | $38.00 | Jul 9, 2025 |
| Needham | Maintained | Buy | $40.00 from $41.00 | May 8, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $40.00 | Apr 9, 2025 |
| Needham | Maintained | Buy | $41.00 | Apr 9, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $40.00 from $45.00 | Mar 14, 2025 |
| Needham | Maintained | Buy | $41.00 | Mar 13, 2025 |
Frequently asked questions
What is the price target for RNAC stock?
The average 12-month analyst price target for Cartesian Therapeutics (RNAC) is $40.67, with a high estimate of $44.00 and a low of $38.00, across 3 analysts.
Is RNAC a buy, sell, or hold?
Analysts covering Cartesian Therapeutics currently average a Buy rating: 8 buy, 0 hold and 0 sell, from 8 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for RNAC?
The average price target of $40.67 implies 338.22% upside from the last price of $9.28.
What is the latest analyst rating on RNAC?
On Aug 18, 2026, Wedbush maintained Cartesian Therapeutics at Outperform with a price target of $38.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.